The estimated Net Worth of Rui Avelar is at least $8.77 millió dollars as of 10 May 2024. Rui Avelar owns over 3,441 units of Evolus Inc stock worth over $5,632,294 and over the last 6 years he sold EOLS stock worth over $1,302,305. In addition, he makes $1,836,610 as Chief Medical Officer és Head of Research & Development at Evolus Inc.
Sign up
Rui Avelar EOLS stock SEC Form 4 insiders trading
Rui has made over 10 trades of the Evolus Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 3,441 units of EOLS stock worth $43,770 on 10 May 2024.
The largest trade he's ever made was selling 39,442 units of Evolus Inc stock on 7 January 2020 worth over $422,424. On average, Rui trades about 7,449 units every 95 days since 2019. As of 10 May 2024 he still owns at least 368,847 units of Evolus Inc stock.
You can see the complete history of Rui Avelar stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Rui Avelar biography
Dr. Rui L. Avelar M.D. serves as Chief Medical Officer, Head of Research & Development of the Company. From March 2011 to December 2013, he served as Chief Medical Officer of Allergan Medical, where he was responsible for clinical development, clinical operations, safety, medical writing, biostatistics and regulatory matters. Dr. Avelar holds a M.D. from the University of Toronto and has received training accreditation in Sports Medicine from the Canadian Academy of Sports Medicine.
What is the salary of Rui Avelar?
As the Chief Medical Officer és Head of Research & Development of Evolus Inc, the total compensation of Rui Avelar at Evolus Inc is $1,836,610. There are 2 executives at Evolus Inc getting paid more, with Michael Jafar having the highest compensation of $3,929,160.
What's Rui Avelar's mailing address?
Rui's mailing address filed with the SEC is 520 Newport Center Dr #1200, Newport Beach, CA 92660, USA.
Insiders trading at Evolus Inc
Over the last 7 years, insiders at Evolus Inc have traded over $244,915,132 worth of Evolus Inc stock and bought 3,308,677 units worth $53,545,237 . The most active insiders traders include Biopharma, Inc. Aeon, Inc. Medytox és 1 Llc Alphaeon. On average, Evolus Inc executives and independent directors trade stock every 25 days with the average trade being worth of $3,606,270. The most recent stock trade was executed by Sandra Beaver on 6 September 2024, trading 3,276 units of EOLS stock currently worth $49,074.
What does Evolus Inc do?
evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.
What does Evolus Inc's logo look like?
Complete history of Rui Avelar stock trades at Evolus Inc
Evolus Inc executives and stock owners
Evolus Inc executives and other stock owners filed with the SEC include:
-
Michael Jafar,
Chief Commercial Officer -
David Moatazedi,
President, Chief Executive Officer, Director -
Rui Avelar,
Chief Medical Officer, Head of Research & Development -
David Moatazedi,
Pres, CEO & Director -
Lauren Silvernail,
Chief Financial Officer, Executive Vice President - Corporate Development -
Lauren P. Silvernail,
CFO & Exec. VP of Corp. Devel. -
Dr. Rui Avelar Dip.SportMed, M.D., C.CFP,
Chief Medical Officer and Head of R&D -
Karah Parschauer,
Independent Director -
Peter Farrell,
Independent Director -
Vikram Malik,
Chairman of the Board -
David Gill,
Independent Director -
Robert Hayman,
Independent Director -
Simone Blank,
Director -
Tram Bui,
IR Contact Officer -
Jeff Plumer,
General Counsel -
Jessica Novak,
Sr. VP of HR -
Crystal Muilenburg,
Chief Marketing Officer -
Kurt Knab,
VP of Sales -
Jeffrey J. Plumer,
Gen. Counsel -
David K. Erickson,
VP of Investor Relations -
Biopharma, Inc. Aeon,
-
Sandra Beaver,
Chief Financial Officer -
Crystal Muilenburg,
Chief Marketing Officer -
Albert G Iii White,
Director -
Kristine Romine,
Director -
Bosun Hau,
Director -
1 Llc Alphaeon,
-
Brady Stewart,
Director -
Tomoko Yamagishi Dressler,
Chief Marketing Officer -
Inc. Medytox,